Climb Bio Inc
CLYM
NASDAQ
Biotechnology
$16.33
USD
+1.60 (+10.86%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $846.04M
Volume 2.5M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-57.62M
TTM
— YoY
Operating Cash Flow
$-52.70M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.1 | 5.8 | 5.6 | 5.8 | 5.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 10.7 | 14.9 | 19.3 | 15.2 | 15.4 |
Operating Income | -10.7 | -14.9 | -19.3 | -15.2 | -15.4 |
EBITDA | -10.6 | -14.9 | -19.3 | -15.2 | -15.3 |
Other Income / Expense | -0.2 | -0.0 | -0.0 | -0.0 | 0.0 |
Total Other Income / Expense | 2.0 | 2.0 | 1.8 | 1.5 | 1.9 |
Income Before Income Taxes | -8.7 | -12.9 | -17.5 | -13.7 | -13.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -8.7 | -12.9 | -17.5 | -13.7 | -13.5 |
Consolidated Net Income / Loss | -8.7 | -12.9 | -17.5 | -13.7 | -13.5 |
Net Income Attributable to Common Shareholders | -8.7 | -12.9 | -17.5 | -13.7 | -13.5 |
Basic EPS | -$0.13 | -$0.19 | -$0.26 | -$0.20 | -$0.18 |
Diluted EPS | -$0.13 | -$0.19 | -$0.26 | -$0.20 | -$0.18 |
Basic Shares Outstanding | 67.6M | 68.0M | 68.2M | 68.2M | 76.2M |
Diluted Shares Outstanding | 67.6M | 68.0M | 68.2M | 68.2M | 76.2M |